Slingshot members are tracking this event:

An FDA advisory panel has given unanimous support to a one-of-a-kind dissolving heart stent from Abbott Laboratories

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ABT Community voting in process

Additional Information

Additional Relevant Details The FDA voted 9 to 0, with one abstention, that the benefits of Abbott's Absorb fully bioresorbable drug eluting coronary stent outweigh the risks.

The FDA advisory committee panel reviewed data from multiple studies of the Absorb dissolving stent, including ABSORB III, a company-sponsored U.S. clinical trial involving approximately 2,000 people that found the investigational device to be comparable to the market-leading metallic drug-eluting stent, Abbott's Xience drug eluting stent. At one year in ABSORB III, patients who received an Absorb dissolving stent had experienced comparable rates of specific adverse events—including heart disease-related death, heart attacks attributed to the stented artery and repeat procedures (collectively termed target lesion failure)—as compared to patients who received the Xience stent.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Advisory Panel, Fda, Heart Stent, Bioresorbable Drug Eluting Coronary Stent, Absorb Iii, Xience, Target Lesion Failure, Stented Artery, Heart Attack, Heart Disease